Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy

Journal of Neuro-Oncology

Volumn 115, Issue 2, 2013, Pages 261-265

  Ducray, F ^a   Kaloshi, G ^b   Houillier, C ^b   Idbaih, A ^b,c,d   Ribba, B ^e   Psimaras, D ^b   Marie, Y ^b,c,d   Boisselier, B ^b,c,d   Alentorn, A ^b,c,d   Dainese, L ^b   Navarro, S ^b   Mokhtari, K ^b,c,d   Sanson, M ^b,c,d   Hoang Xuan, K ^b,c,d   Delattre, Jean Yves ^b,c,d  

^a UNIVERSITÉ LYON 1   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d CNRS   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

1p19q codeletion; IDH1; Low grade glioma; Mean tumor diameter; Radiotherapy; TP53

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; PROTEIN P53;

1P19Q CODELETION; ADULT; ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; CHROMOSOME DELETION; CLINICAL ARTICLE; FEMALE; GLIOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886594773     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1224-1     Document Type: Article

References (15)

1. Mandonnet E, Delattre JY, Tanguy ML et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524-528
2. Ricard D, Idbaih A, Ducray F et al (2012) Primary brain tumours in adults. Lancet 379:1984-1996
3. Peyre M, Cartalat-Carel S, Meyronet D et al (2010) Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12:1078-1082
4. Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484-490
5. Soffietti R, Baumert BG, Bello L et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124-1133
6. van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583-593
7. Desestret V, Ciccarino P, Ducray F et al (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105:219-224
8. Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-1836
9. Bauman G, Pahapill P, Macdonald D et al (1999) Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci 26:18-22
10. Eyre HJ, Crowley JJ, Townsend JJ et al (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78:909-914
11. Lunsford LD, Somaza S, Kondziolka D et al (1995) Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 82:523-529
12. Pallud J, Llitjos JF, Dhermain F et al (2012) Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14:496-505
13. Ribba B, Kaloshi G, Peyre M et al (2012) A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 18:5071-5080
14. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714
15. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722